These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23734311)

  • 1. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors.
    Spear P; Barber A; Sentman CL
    Oncoimmunology; 2013 Apr; 2(4):e23564. PubMed ID: 23734311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
    Spear P; Barber A; Rynda-Apple A; Sentman CL
    Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.
    Barber A; Sentman CL
    J Immunol; 2009 Aug; 183(4):2365-72. PubMed ID: 19625653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.
    Barber A; Rynda A; Sentman CL
    J Immunol; 2009 Dec; 183(11):6939-47. PubMed ID: 19915047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.
    Spear P; Barber A; Rynda-Apple A; Sentman CL
    J Immunol; 2012 Jun; 188(12):6389-98. PubMed ID: 22586039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.
    Barber A; Zhang T; Sentman CL
    J Immunol; 2008 Jan; 180(1):72-8. PubMed ID: 18097006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
    Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
    Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2007 Nov; 67(22):11029-36. PubMed ID: 18006849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.
    Barber A; Meehan KR; Sentman CL
    Gene Ther; 2011 May; 18(5):509-16. PubMed ID: 21209626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
    Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH
    Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
    Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
    Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
    [No Abstract]   [Full Text] [Related]  

  • 15. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes.
    Zhang L; Sosinowski T; Cox AR; Cepeda JR; Sekhar NS; Hartig SM; Miao D; Yu L; Pietropaolo M; Davidson HW
    J Autoimmun; 2019 Jan; 96():50-58. PubMed ID: 30122420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
    Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
    Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.
    Nesbeth YC; Martinez DG; Toraya S; Scarlett UK; Cubillos-Ruiz JR; Rutkowski MR; Conejo-Garcia JR
    J Immunol; 2010 May; 184(10):5654-62. PubMed ID: 20400704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.
    Liu L; Patel B; Ghanem MH; Bundoc V; Zheng Z; Morgan RA; Rosenberg SA; Dey B; Berger EA
    J Virol; 2015 Jul; 89(13):6685-94. PubMed ID: 25878112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.
    Sentman ML; Murad JM; Cook WJ; Wu MR; Reder J; Baumeister SH; Dranoff G; Fanger MW; Sentman CL
    J Immunol; 2016 Dec; 197(12):4674-4685. PubMed ID: 27849169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.
    Miller CH; Graham L; Bear HD
    BMC Immunol; 2010 Nov; 11():54. PubMed ID: 21050466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.